LONDON & NEW YORK, October 29, 2025--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...
The results of the COMPASS trial testing rivaroxaban plus aspirin in patients with coronary artery disease or peripheral artery disease showed such significant benefits for reducing ischemic events ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results